Almost 50 percent of clinical trials in the region last year were led by biotechs and by 2025, biotech-led clinical trials will far exceed those led…
In Conversation
I always come back to the question of how we help as many patients as possible access the healthcare solutions they need. Within this push, collaboration…
Looking beyond current advances in personalized or stratified cancer therapy, I think that early intervention – before the disease becomes advanced – will be the future…
Singapore is often the first market for [Pfizer's] product launches in Emerging Asia, new regulatory strategies to optimize launch timelines, and digital innovations. We act as…
Healthcare is a key area within our plan moving forward, and this comes as no surprise considering that four percent of the Singaporean economy already comes…
Value-Based healthcare in this part of the world will be implemented in different ways. It will come less through contracts, but more through pricing regulations
We need doctors, nurses and other healthcare providers to be willing to go the extra mile to monitor patients outside of hospital settings
Regulators are in a difficult position and still coming to understand how to define these new technologies. Greater alignment with the US does seem to be…
We are looking for partners who understand the complexity and the challenges we are facing in developing a hardware device. This extends beyond capital to knowledge…
Singapore has always been considered the bellwether of driving innovation in the region, which remains the case. In terms of new oncology and immunology products, Singapore…
The pandemic has forced every industry to rethink its operating model. For us in pharma, COVID-19 really sped up the adoption of digitalisation
During the past 20 years, we have built clusters like Biopolis, universities and institutions and so on. The piece that we are doubling down is in…
